BRAZILIAN
Brazilian Finance Logo
FINANCE

MENU

© 2026 Brazilian Finance

Markets · Stocks & ETFs · ADR

Hypera (OTC: HYPMY)

$4.19-1.41%today

Brazilian ADR trading on the OTC, priced in US dollars.

Display currency
Market Cap, EPS and the financial totals below — switch between US dollars and BRL.
Market Cap
$2.90B
P/E (TTM)
8.2x
P/B
1.1x
EPS (TTM)
$0.51
Dividend Yield
5.01%
52-Week Range
$3.71 – $5.50
Volume
200
Previous Close
$4.25

TTM = trailing twelve months — the most recent 12 months (a rolling window), used for P/E, EPS and dividends. On the tables and charts below, the in-progress current year appears as a “Last 12M” column labelled with the quarter range it covers.

Performance

Today
-1.41%
1 Week
-2.33%
1 Month
+2.70%
YTD
+1.21%
1 Year
-0.71%
5 Years
-35.24%
Hypera logo

About Hypera

US Ticker
HYPMY
B3 Ticker
HYPE3
Exchange
OTC
Currency
USD
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Headquarters
São Paulo, SP, Brazil
Employees
10,564
CEO
Mr. Breno Toledo Pires de Oliveira
Founded
1999

Hypera S.A. operates as a pharmaceutical company in Brazil.

The company provides sweeteners products under the Adocyl, finn, and Zero-cal brands; analgesics and anti-inflammatories products under the Doril, Atroveran, Calminex, Alivium, Buscopan, Buscofem, geloll, Torsilax, Neosaldina, and naprohax brands; cold and flu remedies and decongestants products under BENEGRIO, Rinosoro, Blu, Neosoro, Coristina, APRACUR, and Fluviral brands.

It offers antihistamines products under Alektos, Histamin, Polaramine, PredSim, and Desrinite brands; antiseptics products under Merthiolate brand; Herbal medicine products under Maracugina, Eparema, Tamarine, and Naturetti brands; gastrointestinal products under Dramin, Estomazil, Engov, Lacto-purga, gastrol, Epocler, Bifilax, and Pepsamar brands.

In addition, the company provides generics products under neo quimica brand; skicare products under episol, epidrat, simple organic, and bioage brands; supplements and vitamins products Addera, Biotonico Fontoura, Colflex, and Vitasay brands; and other products under Nebacetin, Cepacol, ESCABIN, Mirrorelax, Ammy, Nesina, and Diprospan brands.

The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018.

Hypera S.A. was founded in 1999 and is headquartered in São Paulo, Brazil.

www.hypera.com.br

Financial Results

Revenue, EBITDA and net profit (in USD) with net margin (net profit ÷ revenue).

Financial Health

Margins, leverage and cash-flow quality derived from Hypera's income statement, balance sheet and cash flow (absolute figures in USD).

ProfitabilityLeverageGrowth

Overall: Financially Strong

Net Margin
19.6%
ROE
11.9%
Rev Growth (YoY)
+13.59%
Net Debt / EBITDA
1.98×
Current Ratio
1.86×
Interest Coverage
2.62×
Free Cash Flow
1.81B
Payout Ratio
43.8%

Income — Margins & Efficiency

MetricLast 12MQ3'25 – Q2'26Δ2025Δ2024Δ2023Δ2022
Revenue$1,690,045,993+20.2%$1,405,930,572+16.7%$1,204,691,886-26.2%$1,631,820,956+14.3%$1,427,989,819
Gross profit$1,029,524,417+24.0%$830,047,661+17.0%$709,140,485-31.1%$1,029,966,599+14.3%$901,018,809
Operating income$477,907,512+50.6%$317,382,309+9.2%$290,676,282-43.6%$515,013,402+10.7%$465,378,647
EBITDA$577,065,144+39.8%$412,871,334+14.4%$361,039,512-39.1%$593,158,220+13.3%$523,461,946
Net profit$331,476,607+51.9%$218,284,394+0.6%$217,062,432-36.1%$339,771,556+5.8%$321,064,414
Gross margin60.9%+1.9 p.p.59.0%+0.2 p.p.58.9%-4.3 p.p.63.1%+0.0 p.p.63.1%
Operating margin28.3%+5.7 p.p.22.6%-1.6 p.p.24.1%-7.4 p.p.31.6%-1.0 p.p.32.6%
EBITDA margin34.1%+4.8 p.p.29.4%-0.6 p.p.30.0%-6.4 p.p.36.3%-0.3 p.p.36.7%
Net margin19.6%+4.1 p.p.15.5%-2.5 p.p.18.0%-2.8 p.p.20.8%-1.7 p.p.22.5%
Revenue growth (YoY)13.6%+10.1 p.p.3.4%+9.4 p.p.-6.0%-10.8 p.p.4.9%——
Effective tax rate-4.3%+28.0 p.p.-32.3%+3.8 p.p.-36.1%-26.7 p.p.-9.4%-3.5 p.p.-5.9%
Interest coverage2.62×+40.6%1.86×-7.3%2.01×-14.0%2.34×-11.3%2.63×

Newest column (“Last 12M”) = trailing 12 months, the last 4 reported quarters — shown with the quarter range it spans; earlier columns are full fiscal years.

Balance Sheet — Health & Leverage

MetricLast 12MQ3'25 – Q2'26Δ2025Δ2024Δ2023Δ2022
Net debt$1,140,830,966-18.8%$1,404,606,844+13.3%$1,239,586,267-18.5%$1,521,781,164+17.9%$1,290,257,730
Net Debt / Equity0.41×-33.4%0.61×-3.0%0.63×-1.3%0.64×+0.2%0.64×
Net Debt / EBITDA1.98×-41.9%3.40×-0.9%3.43×+33.8%2.57×+4.1%2.46×
Debt / Equity0.52×-30.5%0.75×-4.0%0.78×-10.3%0.87×-4.8%0.91×
Current ratio1.86×+26.3%1.47×-13.2%1.70×-2.5%1.74×+6.5%1.63×
Return on equity (ROE)11.9%+2.3 p.p.9.5%-1.5 p.p.11.1%-3.2 p.p.14.3%-1.6 p.p.15.9%
Return on assets (ROA)6.8%+2.0 p.p.4.8%-0.7 p.p.5.5%-1.3 p.p.6.7%-0.4 p.p.7.1%
Book value / share$3.96+10.8%$3.58+16.7%$3.06-17.4%$3.71+17.6%$3.16

Newest column (“Last 12M”) = trailing 12 months, the last 4 reported quarters — shown with the quarter range it spans; earlier columns are full fiscal years.

Net Debt & Leverage

Free Cash Flow

Margins

Dividend Payout Ratio

Capex ÷ Revenue

Cash Conversion (operating cash flow ÷ net income)

Ratios computed from company financial statements. Net Debt = total debt − cash & equivalents; FCF = operating cash flow − capital expenditure; absolute values in USD.

Valuation & Dividends

P/E Ratio History

Dividend History

This year (YTD) $0.16/share · yield 3.77%

Dividends and yield from Yahoo Finance (per ADR share, in US dollars). The current-year figures are calendar year-to-date (dividends actually paid this year), not the trailing 12 months.

Listings

Hypera trades on 2 exchanges. Prices on this page are the OTC ADR (HYPMY).

ExchangeTickerCurrency
OTCpriced hereHYPMYUSD
B3 (São Paulo)HYPE3BRL

Frequently Asked Questions

Why hold Hypera HYPMY ADR instead of local B3 HYPE3 shares?

Buying directly on Brazil’s B3 exchange means opening a local brokerage account, converting currency and dealing with Brazilian tax paperwork. ADRs remove that friction: they settle in dollars, follow US market hours, and report in formats foreign investors already understand.

The trade-off is that an ADR’s price reflects two moving parts: (1) the underlying share price, quoted in reais on the B3, and (2) the USD/BRL exchange rate. Because of that second part, a rising company can still deliver a flat, or even negative, dollar return if the real weakens against the dollar. The same applies to ETFs: funds such as EWZ, EWZS and FLBR bundle dozens of these companies into a single ticker for instant diversification, but their dollar value still moves with the real.

Where is Hypera listed?

Hypera trades on 2 exchanges. The line quoted on this page is OTC in the United States (HYPMY, US dollars). It also trades on B3 (São Paulo) in Brazil (HYPE3, Brazilian reais).

On how many exchanges does Hypera trade?

2. OTC — HYPMY (USD) · B3 (São Paulo) — HYPE3 (BRL). Prices shown on this page are the OTC line, HYPMY.

What is Hypera's primary listing?

Hypera's primary listing is on the B3 in Brazil, where the shares trade as HYPE3 in reais — the company's home market. The OTC line quoted on this page is an ADR over those same shares: it gives you the asset in US dollars, on US market hours, without opening a Brazilian brokerage account or trading in reais.

What is the difference between HYPMY and HYPE3?

They are the same company and, economically, the same asset. HYPE3 is the original Brazilian share, listed on the B3 and quoted in reais. HYPMY is an American Depositary Receipt over that share, listed on the OTC and quoted in US dollars — a wrapper whose purpose is to give foreign investors access to the Brazilian asset without opening an account in Brazil. The HYPMY price therefore tracks two things: HYPE3 in reais, and the USD/BRL exchange rate.

How can I buy Hypera stock in the United States?

Hypera is listed on the OTC under HYPMY, priced in US dollars. Any US brokerage offering over-the-counter securities can trade it, with no foreign-account paperwork and no currency conversion.

As of Fri, Aug 14, 17:00 BRT · Market closed

Financial data last updated: August 14, 2026

← All stocks & ETFs